Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine vs. standard-dose intramuscular vaccine in HIV-1-infected adults

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 8, 2012, Pages 1048-1052

  Ansaldi, Filippo ^a,b   Valle, Laura ^b   De Florentiis, Daniela ^b   Parodi, Valentina ^b   Murdaca, Giuseppe ^a,b   Bruzzone, Bianca M ^a   Durando, Paolo ^a,b   Setti, Maurizio ^a   Icardi, Giancarlo ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

HIV; Immunogenicity; Influenza vaccines; Intradermal injections; Safety; Tolerability

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; VIRUS RNA;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE DRUG DOSE; SKIN INDURATION; SKIN REDNESS; SKIN SWELLING; VIRUS LOAD; VIRUS STRAIN;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD4 LYMPHOCYTE COUNT; DRUG TOXICITY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; RNA, VIRAL; VACCINES, INACTIVATED;

EID: 84866133428     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20347     Document Type: Article

References (25)

1. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents MMWR April 10 2009; 58:4.
2. ECDC SIIP Team. ECDC guidance Priority risk groups for influenza vaccination. Stockholm, August 2008.
3. Bickel M, von Hentig N, Wieters I, Khaykin P, Nisius G, Haberl A, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011; 52:122-7; PMID:21148530; http://dx.doi.org/10.1093/cid/ciq003.
4. Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, Faix D, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-46; PMID:21148532; http://dx.doi.org/10.1093/cid/ciq019.
5. Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, et al.; CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One 2011; 6:17758; PMID:21512577; http://dx.doi.org/10.1371/journal.pone.0017758.
6. Lenz A, Heine M, Schuler G, Romani N. Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 1993; 92:2587-96; PMID:8254016; http://dx.doi.org/10.1172/JCI116873.
7. Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets [Erratum in: J Immunol 1994; 152:376]. J Immunol 1993; 151:6535-45; PMID:7504023.
8. Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007; 25:6755-63; PMID:17692438; http://dx.doi.org/10.1016/j.vaccine.2007.06.066.
9. Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008; 26:6614-9; PMID:18930093; http://dx.doi.org/10.1016/j.vaccine.2008.09.078.
10. Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009; 7:13; PMID:19341446; http://dx.doi.org/10.1186/1741-7015-7- 13.
11. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. Hum Vaccin 2010; 6:346-54; PMID:20372053; http://dx.doi.org/10.4161/hv.6. 4.10961.
12. Frenck RW Jr, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011; 29:5666-74; PMID:21699951; http://dx.doi.org/10.1016/j.vaccine.2011.06.010.
13. Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials. Hum Vaccin 2010; 6:336-45; PMID:20372083; http://dx.doi.org/10.4161/hv.6.4.10753.
14. Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther 2011; 28:640-9; PMID:21751080; http://dx.doi.org/10.1007/s12325-011-0042-0.
15. Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, Ellefsen K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248-56; PMID:21288852; http://dx.doi.org/10.1093/cid/ciq104.
16. Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine 2011; 29:9209-13; PMID:21974995; http://dx.doi.org/10.1016/j.vaccine.2011.09.103.
17. Soonawala D, Rimmelzwaan GF, Gelinck LBS, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011; 6:16496; PMID:21304982; http://dx.doi.org/10.1371/journal.pone.0016496.
18. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality and vaccine responses. Lancet Infect Dis 2009; 9:493-504; PMID:19628174; http://dx.doi.org/10.1016/ S1473-3099(09)70175-6.
19. Ho DD. HIV-1 viraemia and influenza.Lancet1992; 339:1549; PMID:1351231; http://dx.doi.org/10.1016/0140-6736(92)91321-X.
20. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999; 28:541-7; PMID:10194075; http://dx.doi.org/10.1086/515170.
21. Couch RB. Influenza, influenza virus vaccine and human immunodeficiency virus infection. Clin Infect Dis 1999; 28:548-51; PMID:10194076; http://dx.doi.org/10.1086/515171.
22. Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008; 15:253-9; PMID:18003811; http://dx.doi.org/10.1128/CVI.00316-07.
23. Yanagisawa N, Maeda K, Ajisawa A, Imamura A, Suganuma A, Ando M, et al. Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. Vaccine 2011; 29:5694-8; PMID:21689709; http://dx.doi.org/10.1016/j.vaccine.2011.06.003.
24. Zambon M. Laboratory diagnosis of influenza. In: Textbook of influenza. Nicholson KG, Webster RG, Hay AJ, (Editors). Oxford: Blackwell Science 1998; 291-313.
25. World Health Organization Global Influenza Programme. WHO manual on animal influenza diagnosis and surveillance; 2002. WHO/CDS/NCS/2002/5.